Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?

Abstract

This study was conducted to evaluate the expression of fibrinogen receptors on platelets of Philadelphia-negative chronic myeloproliferative neoplasm (MPN) patients. We collected blood samples from 40 consecutive MPN patients and healthy volunteers. We performed flow cytometry analysis of P-selectin expression and integrin beta-3, activation of glycoprotein (GP) IIb/IIIa and fibrinogen receptor exposure (PAC-1 binding). Surprisingly, we found a very low PAC-1 binding capacity in MPN patients; however, the expression of PAC-1 was almost completely recovered with aspirin intake. We hypothesize that the hypercoagulable states observed in MPN patients could depend on a primarily plasma-driven impairment of fibrin turnover and thrombin generation.

• Authors: Alessandro Lucchesi, Silvia Carloni, Serena De Matteis, Martina Ghetti, Gerardo Musuraca, Monica Poggiaspalla, Accursio F Augello, Giulio Giordano, Pier P Fattori, Giovanni Martinelli, Roberta Napolitano
• Journal: British journal of haematology (Br J Haematol) Vol. 189 Issue 2 Pg. 335-338 (04 2020) ISSN: 1365-2141 [Electronic] England
• PMID: 31792942 (Publication Type: Journal Article)
• Copyright: © 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Chemical References

• Fibrinogen
• Aspirin

Topics

• Adult
• Aged
• Aged, 80 and over
• Aspirin (pharmacology, therapeutic use)
• Blood Platelets
• Chronic Disease
• Fibrinogen (pharmacology, therapeutic use)
• Humans
• Middle Aged
• Myeloproliferative Disorders (drug therapy)